Free Trial
NASDAQ:LNTH

Lantheus (LNTH) Stock Price, News & Analysis

Lantheus logo
$87.32 +0.87 (+1.01%)
(As of 11/21/2024 ET)

About Lantheus Stock (NASDAQ:LNTH)

Key Stats

Today's Range
$85.24
$88.52
50-Day Range
$76.22
$116.69
52-Week Range
$50.20
$126.89
Volume
1.46 million shs
Average Volume
1.02 million shs
Market Capitalization
$6.07 billion
P/E Ratio
14.53
Dividend Yield
N/A
Price Target
$122.50
Consensus Rating
Moderate Buy

Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Lantheus Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
92nd Percentile Overall Score

LNTH MarketRank™: 

Lantheus scored higher than 92% of companies evaluated by MarketBeat, and ranked 102nd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Lantheus has only been the subject of 3 research reports in the past 90 days.

  • Read more about Lantheus' stock forecast and price target.
  • Earnings Growth

    Earnings for Lantheus are expected to grow by 2.52% in the coming year, from $5.96 to $6.11 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lantheus is 14.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lantheus is 14.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 129.18.

  • Price to Book Value per Share Ratio

    Lantheus has a P/B Ratio of 5.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Lantheus' valuation and earnings.
  • Percentage of Shares Shorted

    6.03% of the outstanding shares of Lantheus have been sold short.
  • Short Interest Ratio / Days to Cover

    Lantheus has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Lantheus has recently decreased by 1.41%, indicating that investor sentiment is improving.
  • Dividend Yield

    Lantheus does not currently pay a dividend.

  • Dividend Growth

    Lantheus does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.03% of the outstanding shares of Lantheus have been sold short.
  • Short Interest Ratio / Days to Cover

    Lantheus has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Lantheus has recently decreased by 1.41%, indicating that investor sentiment is improving.
  • News Sentiment

    Lantheus has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Lantheus this week, compared to 7 articles on an average week.
  • Search Interest

    28 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lantheus insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.50% of the stock of Lantheus is held by insiders.

  • Percentage Held by Institutions

    99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lantheus' insider trading history.
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Stock News Headlines

Lantheus To Repurchase Up To $250 Mln Of Shares
Why Lantheus Holdings Stock Won Big on Wednesday
What Comes Next Could Be a Once-in-a-Lifetime Opportunity
A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.
Lantheus Announces Share Repurchase Program
See More Headlines

LNTH Stock Analysis - Frequently Asked Questions

Lantheus' stock was trading at $62.00 on January 1st, 2024. Since then, LNTH stock has increased by 40.8% and is now trading at $87.32.
View the best growth stocks for 2024 here
.

Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings data on Wednesday, July, 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by $0.07. Lantheus's revenue for the quarter was up 22.5% compared to the same quarter last year.

Lantheus (LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Lantheus' top institutional shareholders include Janus Henderson Group PLC (5.16%), Geode Capital Management LLC (2.42%), Westfield Capital Management Co. LP (2.18%) and Reinhart Partners LLC. (1.79%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Etienne Montagut, Andrea Sabens, Heinz Christoph Maeusli, Gerard Ber, Brian A Markison, Gary J Pruden, Minnie Baylor-Henry and Carol Walker.
View institutional ownership trends
.

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
7/31/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/27/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LNTH
Employees
834
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$122.50
High Stock Price Target
$175.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+39.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$326.66 million
Pretax Margin
38.09%

Debt

Sales & Book Value

Annual Sales
$1.30 billion
Cash Flow
$7.43 per share
Book Value
$16.97 per share

Miscellaneous

Free Float
68,484,000
Market Cap
$6.09 billion
Optionable
Optionable
Beta
0.51
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:LNTH) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners